| Bioactivity | NS-102 is a selective kainate (GluK2) receptor antagonist. NS-102 is a potent GluR6/7 receptor antagonist[1][2][3]. | ||||||||||||
| Invitro | Combination of NS-102 (10 μM) and GYKI 52466 (30 μM) preventes full loss of compound action potentials (CAPs) during oxygen and glucose deprivation (OGD) and increases CAP area recovery[1]. | ||||||||||||
| In Vivo | NS-102 (20, 40 or 80 μmol/litre ; in the hippocampal CA3 region) significantly reduces Sevoflurane-induced hyperactivities[1]. | ||||||||||||
| Name | NS-102 | ||||||||||||
| CAS | 136623-01-3 | ||||||||||||
| Formula | C12H11N3O4 | ||||||||||||
| Molar Mass | 261.23 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Selva Baltan Tekkök, et al. Excitotoxic mechanisms of ischemic injury in myelinated white matter. J Cereb Blood Flow Metab. 2007 Sep;27(9):1540-52. [2]. P Liang, et al. Sevoflurane activates hippocampal CA3 kainate receptors (Gluk2) to induce hyperactivity during induction and recovery in a mouse model. Br J Anaesth. 2017 Nov 1;119(5):1047-1054. [3]. Barbara Gisabella, et al. Kainate receptor-mediated modulation of hippocampal fast spiking interneurons in a rat model of schizophrenia. PLoS One. 2012;7(3):e32483. |